Skip to main content

Advertisement

Log in

Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations

  • Original Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

Successful treatment of vascular anomalies has eluded the physician until now, despite various treatments utilised. Bleomycin has been successfully used in intralesional injection treatment of cystic hygromas and haemangiomas, based specifically on a high sclerosing effect on vascular endothelium. In a prospective study of 95 patients, the effectiveness of intralesional bleomycin injection (IBI) treatment in haemangiomas and vascular malformations was evaluated and documented. Complete resolution or significant improvement occurred in 80% of all patients treated. Complete resolution occurred in 49% of haemangiomas, 32% of venous malformations, and 80% of cystic hygromas. Significant improvement occurred in 38% of haemangiomas, 52% of venous malformations, 13% of cystic hygromas and 50% of lymphatic malformations. Of the six patients who presented with a painful lesion, four experienced complete resolution and two had significant improvement to treatment. Local complications encountered were superficial ulceration occurring in 2 patients, and cellulitis in 1 of the 95 patients. Systemic complications were flu-like symptoms in three patients and partial, transient hair loss in two patients. None of the patients presented with haematological toxic effects or signs of pulmonary involvement (fibrosis, hypertension). IBI is an effective treatment in haemangiomas and vascular malformation lesions, obviating the need for invasive primary surgery or systemic treatment regimens in 80% of cases, and allowing for limited need of secondary surgical or adjunctive procedures in cases with a moderate result.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Umezawa H (1966) Purification of bleomycins. J Antibiot 19:21–215

    Google Scholar 

  2. Blum R (1973) A clinical review of Bleomycin—a new antineoplastic agent. Cancer 31:903–914

    CAS  PubMed  Google Scholar 

  3. Lopez-larraza D (1990) The kinetics of DNA damage by bleomycin in mammalian cells. Mutation Research 232:57–61

    CAS  PubMed  Google Scholar 

  4. Yura J (1977) Bleomycin treatment for cystic hygroma in children. Arch Jap Chir 5 (46): 607–614

    Google Scholar 

  5. Tanigawa N (1987) Treatment of cystic hygroma and lymphangioma with the use of Bleomycin fat emulsion. Cancer 15:741–749

    Google Scholar 

  6. Tanaka K (1990) Sclerosing therapy with Bleomycin emulsion for lymphangioma in children. Ped Surg Int 5:270–273

    Google Scholar 

  7. Okada A (1992) Injection of Bleomycin as a primary therapy of cystic lymphangioma. J Ped Surg 27 (4): 440–443

    CAS  Google Scholar 

  8. Orford J (1995) Bleomycin therapy for cystic hygroma. J Ped Surg 30 (9):1282–1287

    CAS  Google Scholar 

  9. Sarihan H (1997) A new treatment with Bleomycin for complicated cutaneous hemangioma in children. Eur J Ped Surg 7:158–162

    CAS  Google Scholar 

  10. Kullendorf C (1997) Efficacy of Bleomycin treatment for symptomatic hemangiomas in children. Ped Surg Int 12:526–528

    Article  Google Scholar 

  11. Qin ZP (1998) Long term results of intratumorous Bleomycin-A5 injection for head and neck lymphangioma. Mosby Year Book 86 (2): 139–144

    Google Scholar 

  12. Enjolras O (1981) Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol 24:701–710

    Google Scholar 

  13. Mulliken JB (2000) Current problems in surgery. 37(8):517–584

  14. Huston III J (1992) Magnetic resonance imaging of facial vascular anomalies. Mayo Clin Proc 67:739–747

    PubMed  Google Scholar 

  15. Metry DW, Hebert AA, (2000) Benign cutaneous vascular tumours of infancy. Arch Dermatol.136:905–914

    Google Scholar 

  16. Sloan GM et al (1989) Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg 83:459–467

    CAS  PubMed  Google Scholar 

  17. Boon LM (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 104:1616–1623

    Google Scholar 

  18. Rogers M (2000) Treatment of ‘angiomas’:a modern commentary. Austral J Dermatol 41 [Suppl]:S89–S91

  19. Weiss AH (1989) Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol 107:518–522

    CAS  PubMed  Google Scholar 

  20. Shorr N (1986) Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 14:229–231

    Google Scholar 

  21. Greinwald JH et al (1999) An update on the treatment of hemangiomas in children with interferon alpha-2a. Arch Otolaryngol Head Neck Surg 125:21–27

    PubMed  Google Scholar 

  22. Scheepers JH et al (1995) Does the pulsed tunable laser have a role in the management of infantile hemangiomas? Observations based on 3 years’ experience.Plast Reconstr Surg 95:305–312

    CAS  PubMed  Google Scholar 

  23. Drolet BA et al (1999) Hemangiomas in children. N Engl J Med 341:173–181

    Article  CAS  PubMed  Google Scholar 

  24. Berenguer B et al (1999) Sclerotherapy of craniofacial venous malformations:complications and results. Plast Reconstr Surg 104:1–11

    CAS  PubMed  Google Scholar 

  25. Mason KP et al (2000) Serum ethanol levels in children and adults after ethanol embolisation or sclerotherapy for vascular anomalies. Radiology 217:127–132

    CAS  PubMed  Google Scholar 

  26. Luce JK (1969) Clinical trial of bleomycin in solid tumors and lymphomas. Proc Am Assoc Cancer Res10:38

    Google Scholar 

  27. Muggia FM (1983) Pulmonary toxicity of antitumour agents. Cancer Tr Rev 10:221–243

    CAS  Google Scholar 

  28. Ugur Ö et al (1993) Bleomycin lung toxicity detected by technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy. Eur J Nucl Med 20:114–118

    CAS  PubMed  Google Scholar 

  29. Gangopadhyay AN et al (1997) Role of steroid in childhood haemangioma: a 10 years review. Int Surg 82:49–51

    CAS  PubMed  Google Scholar 

  30. Enjolras O et al (1990) Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 85:491–498

    CAS  PubMed  Google Scholar 

  31. Gelbert F et al (2000) Percutaneous sclerotherapy for venous malformation of the lips: a retrospective study of 23 patients. Interv Neurorad 42:692–696

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T. Muir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muir, T., Kirsten, M., Fourie, P. et al. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Ped Surgery Int 19, 766–773 (2004). https://doi.org/10.1007/s00383-003-1058-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-003-1058-6

Keywords

Navigation